Inflection Biosciences Announces Pre-Clinical Data for IBL-202 in Mature T-Cell Lymphoma Published in European Journal of Haematology
- Inflection Biosciences
- Apr 6
- 2 min read
Dublin, Ireland, April 6 2025 Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of cancer, autoimmune and inflammatory diseases today announced the
publication of a paper showing pre-clinical data on the company’s first-in-class dual PIM/PI3K inhibitor, IBL-202, as a potential treatment for mature T-cell lymphoma (mTCL).
The paper titled “Dual targeting of Pim and PI3 kinases in mature T-cell lymphoma” provides mechanistic evidence supporting dual inhibition of PIM- and PI3-kinases as a novel therapeutic strategy in mTCL can be accessed at https://onlinelibrary.wiley.com/doi/10.1111/ejh.14420. The data was generated through a collaboration between Inflection and the University Medical Center, Göttingen, Germany, led by PD Dr. med. Raphael Koch, Max-Eder Research Group Leader, Hematology and Oncology. The collaboration was funded by Inflection Biosciences, University Medical Center, Göttingen, German Research Foundation (DFG), German Cancer Aid and Volkswagen Foundation. Dr. Raphael Koch commented “The data shows that the dual inhibition of PIM kinases and the PI3K/AKT pathway is a promising therapeutic strategy for mTCL. One challenging factor in mTCL treatment is the heterogeneity of this entity, making it hard to find drugs that target the different subtypes. IBL-202 showed cytotoxic effects on all tested mTCL lines, across different subtypes.” Mature T-cell lymphoma is as a diverse subgroup of aggressive non-Hodgkin lymphomas that develop from mature white blood cells (T-cells) or natural killer (NK) cells. Due to specific clinical pictures, the different subtypes are considered as separate diseases, carrying different genetic profiles. According to the World Health Organisation, the majority of peripheral T-cell lymphoma subtypes have poor prognosis, with a 5-year overall survival of about 30%.
About Inflection Biosciences
Inflection Biosciences Ltd. is developing small molecule therapeutics for the treatment of cancer, autoimmune and inflammatory diseases. AUM302, partnered with AUM Biosciences, is a first-in-class PIM/PI3K/mTOR inhibitor in development for the treatment of cancer. IBL-202 is a first-in-class, dual PIM kinase and PI3K inhibitor in development for aggressive B-cell malignancies, T-cell lymphoma and acute myeloid leukemia. IBL-100s is a pan-PIM kinase inhibitor program in preclinical development for the treatment of autoimmune diseases. For more information, please visit www.inflectionbio.com
For further information contact:
Inflection Biosciences Ltd
Darren Cunningham, Director
T: +353 (0)1 4003615